nodes	percent_of_prediction	percent_of_DWPC	metapath
Latanoprost—SLCO2B1—Erlotinib—kidney cancer	0.529	1	CbGbCtD
Latanoprost—PTGFR—Prostaglandin Synthesis and Regulation—ANXA4—kidney cancer	0.00511	0.171	CbGpPWpGaD
Latanoprost—PTGFR—Prostaglandin Synthesis and Regulation—ANXA2—kidney cancer	0.00268	0.0897	CbGpPWpGaD
Latanoprost—SLC22A1—Neurotransmitter Clearance In The Synaptic Cleft—ACHE—kidney cancer	0.00187	0.0625	CbGpPWpGaD
Latanoprost—Toxic epidermal necrolysis—Sorafenib—kidney cancer	0.00179	0.00407	CcSEcCtD
Latanoprost—SLC22A1—Abacavir transmembrane transport—ABCB1—kidney cancer	0.00179	0.0597	CbGpPWpGaD
Latanoprost—Hepatic function abnormal—Gemcitabine—kidney cancer	0.00176	0.00399	CcSEcCtD
Latanoprost—Erythema—Pazopanib—kidney cancer	0.00175	0.00397	CcSEcCtD
Latanoprost—Toxic epidermal necrolysis—Sunitinib—kidney cancer	0.00173	0.00392	CcSEcCtD
Latanoprost—Conjunctivitis—Everolimus—kidney cancer	0.00172	0.0039	CcSEcCtD
Latanoprost—Urinary tract infection—Everolimus—kidney cancer	0.00172	0.0039	CcSEcCtD
Latanoprost—Eye irritation—Capecitabine—kidney cancer	0.0017	0.00387	CcSEcCtD
Latanoprost—Conjunctivitis—Erlotinib—kidney cancer	0.00166	0.00376	CcSEcCtD
Latanoprost—Vision blurred—Pazopanib—kidney cancer	0.00165	0.00374	CcSEcCtD
Latanoprost—Dry eye—Paclitaxel—kidney cancer	0.00164	0.00372	CcSEcCtD
Latanoprost—Toxic epidermal necrolysis—Dactinomycin—kidney cancer	0.00163	0.00371	CcSEcCtD
Latanoprost—SLC22A1—Neurotransmitter Clearance In The Synaptic Cleft—BCHE—kidney cancer	0.00163	0.0544	CbGpPWpGaD
Latanoprost—Bronchitis—Sunitinib—kidney cancer	0.00159	0.00361	CcSEcCtD
Latanoprost—Arthralgia—Temsirolimus—kidney cancer	0.00158	0.00359	CcSEcCtD
Latanoprost—Chest pain—Temsirolimus—kidney cancer	0.00158	0.00359	CcSEcCtD
Latanoprost—Lacrimation increased—Capecitabine—kidney cancer	0.00158	0.00358	CcSEcCtD
Latanoprost—Unspecified disorder of skin and subcutaneous tissue—Temsirolimus—kidney cancer	0.00157	0.00356	CcSEcCtD
Latanoprost—Connective tissue disorder—Everolimus—kidney cancer	0.00156	0.00354	CcSEcCtD
Latanoprost—PTGFR—Prostaglandin Synthesis and Regulation—PTGS1—kidney cancer	0.00154	0.0515	CbGpPWpGaD
Latanoprost—Upper respiratory tract infection—Sunitinib—kidney cancer	0.00154	0.00349	CcSEcCtD
Latanoprost—Oedema—Temsirolimus—kidney cancer	0.00152	0.00344	CcSEcCtD
Latanoprost—PTGFR—Prostaglandin Synthesis and Regulation—ANXA1—kidney cancer	0.00151	0.0505	CbGpPWpGaD
Latanoprost—Connective tissue disorder—Erlotinib—kidney cancer	0.0015	0.00341	CcSEcCtD
Latanoprost—Inflammation—Capecitabine—kidney cancer	0.0015	0.0034	CcSEcCtD
Latanoprost—Chest pain—Pazopanib—kidney cancer	0.00149	0.00338	CcSEcCtD
Latanoprost—Arthralgia—Pazopanib—kidney cancer	0.00149	0.00338	CcSEcCtD
Latanoprost—Nervous system disorder—Temsirolimus—kidney cancer	0.00149	0.00337	CcSEcCtD
Latanoprost—Unspecified disorder of skin and subcutaneous tissue—Pazopanib—kidney cancer	0.00148	0.00336	CcSEcCtD
Latanoprost—Skin disorder—Temsirolimus—kidney cancer	0.00147	0.00334	CcSEcCtD
Latanoprost—Embolism—Doxorubicin—kidney cancer	0.00146	0.00332	CcSEcCtD
Latanoprost—Keratitis—Doxorubicin—kidney cancer	0.00145	0.00328	CcSEcCtD
Latanoprost—Urinary tract infection—Sunitinib—kidney cancer	0.00144	0.00326	CcSEcCtD
Latanoprost—Mediastinal disorder—Everolimus—kidney cancer	0.00143	0.00325	CcSEcCtD
Latanoprost—Oedema—Pazopanib—kidney cancer	0.00143	0.00324	CcSEcCtD
Latanoprost—Eye pain—Paclitaxel—kidney cancer	0.00143	0.00324	CcSEcCtD
Latanoprost—Nervous system disorder—Pazopanib—kidney cancer	0.0014	0.00318	CcSEcCtD
Latanoprost—Skin disorder—Pazopanib—kidney cancer	0.00139	0.00315	CcSEcCtD
Latanoprost—Toxic epidermal necrolysis—Gemcitabine—kidney cancer	0.00138	0.00314	CcSEcCtD
Latanoprost—Erythema—Everolimus—kidney cancer	0.00138	0.00313	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Temsirolimus—kidney cancer	0.00138	0.00313	CcSEcCtD
Latanoprost—Mediastinal disorder—Erlotinib—kidney cancer	0.00138	0.00313	CcSEcCtD
Latanoprost—Connective tissue disorder—Sorafenib—kidney cancer	0.00135	0.00307	CcSEcCtD
Latanoprost—Dyspnoea—Temsirolimus—kidney cancer	0.00135	0.00307	CcSEcCtD
Latanoprost—Dry eye—Capecitabine—kidney cancer	0.00134	0.00305	CcSEcCtD
Latanoprost—Back pain—Everolimus—kidney cancer	0.00134	0.00303	CcSEcCtD
Latanoprost—Erythema—Erlotinib—kidney cancer	0.00133	0.00302	CcSEcCtD
Latanoprost—Connective tissue disorder—Sunitinib—kidney cancer	0.0013	0.00296	CcSEcCtD
Latanoprost—Vision blurred—Everolimus—kidney cancer	0.0013	0.00295	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Pazopanib—kidney cancer	0.0013	0.00295	CcSEcCtD
Latanoprost—Pain—Temsirolimus—kidney cancer	0.0013	0.00294	CcSEcCtD
Latanoprost—Back pain—Erlotinib—kidney cancer	0.00129	0.00293	CcSEcCtD
Latanoprost—Dyspnoea—Pazopanib—kidney cancer	0.00127	0.00289	CcSEcCtD
Latanoprost—Dermatitis atopic—Doxorubicin—kidney cancer	0.00127	0.00288	CcSEcCtD
Latanoprost—Mediastinal disorder—Sorafenib—kidney cancer	0.00124	0.00282	CcSEcCtD
Latanoprost—Pain—Pazopanib—kidney cancer	0.00122	0.00277	CcSEcCtD
Latanoprost—Hepatic function abnormal—Capecitabine—kidney cancer	0.00121	0.00274	CcSEcCtD
Latanoprost—Erythema—Sorafenib—kidney cancer	0.0012	0.00272	CcSEcCtD
Latanoprost—Mediastinal disorder—Sunitinib—kidney cancer	0.00119	0.00271	CcSEcCtD
Latanoprost—Chest pain—Everolimus—kidney cancer	0.00118	0.00267	CcSEcCtD
Latanoprost—Arthralgia—Everolimus—kidney cancer	0.00118	0.00267	CcSEcCtD
Latanoprost—Eye pain—Capecitabine—kidney cancer	0.00117	0.00266	CcSEcCtD
Latanoprost—Unspecified disorder of skin and subcutaneous tissue—Everolimus—kidney cancer	0.00117	0.00265	CcSEcCtD
Latanoprost—Discomfort—Vinblastine—kidney cancer	0.00117	0.00265	CcSEcCtD
Latanoprost—Discomfort—Everolimus—kidney cancer	0.00116	0.00264	CcSEcCtD
Latanoprost—Toxic epidermal necrolysis—Paclitaxel—kidney cancer	0.00116	0.00263	CcSEcCtD
Latanoprost—Stinging—Doxorubicin—kidney cancer	0.00116	0.00263	CcSEcCtD
Latanoprost—Erythema—Sunitinib—kidney cancer	0.00115	0.00262	CcSEcCtD
Latanoprost—Arthralgia—Erlotinib—kidney cancer	0.00113	0.00258	CcSEcCtD
Latanoprost—Chest pain—Erlotinib—kidney cancer	0.00113	0.00258	CcSEcCtD
Latanoprost—Oedema—Everolimus—kidney cancer	0.00113	0.00256	CcSEcCtD
Latanoprost—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—kidney cancer	0.00113	0.00256	CcSEcCtD
Latanoprost—Back pain—Sunitinib—kidney cancer	0.00112	0.00253	CcSEcCtD
Latanoprost—Nervous system disorder—Everolimus—kidney cancer	0.00111	0.00251	CcSEcCtD
Latanoprost—Connective tissue disorder—Vincristine—kidney cancer	0.0011	0.0025	CcSEcCtD
Latanoprost—Skin disorder—Everolimus—kidney cancer	0.0011	0.00249	CcSEcCtD
Latanoprost—Erythema—Dactinomycin—kidney cancer	0.00109	0.00248	CcSEcCtD
Latanoprost—Oedema—Erlotinib—kidney cancer	0.00109	0.00247	CcSEcCtD
Latanoprost—Pruritus—Temsirolimus—kidney cancer	0.00107	0.00243	CcSEcCtD
Latanoprost—Bronchitis—Paclitaxel—kidney cancer	0.00107	0.00243	CcSEcCtD
Latanoprost—Nervous system disorder—Erlotinib—kidney cancer	0.00107	0.00242	CcSEcCtD
Latanoprost—Skin disorder—Erlotinib—kidney cancer	0.00106	0.0024	CcSEcCtD
Latanoprost—Diplopia—Capecitabine—kidney cancer	0.00106	0.0024	CcSEcCtD
Latanoprost—Connective tissue disorder—Gemcitabine—kidney cancer	0.00105	0.00237	CcSEcCtD
Latanoprost—Upper respiratory tract infection—Paclitaxel—kidney cancer	0.00103	0.00235	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Everolimus—kidney cancer	0.00103	0.00233	CcSEcCtD
Latanoprost—SLC22A1—Abacavir transport and metabolism—ABCB1—kidney cancer	0.00103	0.0343	CbGpPWpGaD
Latanoprost—Arthralgia—Sorafenib—kidney cancer	0.00102	0.00232	CcSEcCtD
Latanoprost—Lacrimation increased—Doxorubicin—kidney cancer	0.00102	0.00231	CcSEcCtD
Latanoprost—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—kidney cancer	0.00101	0.0023	CcSEcCtD
Latanoprost—Mediastinal disorder—Vincristine—kidney cancer	0.00101	0.00229	CcSEcCtD
Latanoprost—Pruritus—Pazopanib—kidney cancer	0.00101	0.00229	CcSEcCtD
Latanoprost—Dyspnoea—Everolimus—kidney cancer	0.00101	0.00228	CcSEcCtD
Latanoprost—Dizziness—Temsirolimus—kidney cancer	0.001	0.00227	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Erlotinib—kidney cancer	0.000991	0.00225	CcSEcCtD
Latanoprost—Arthralgia—Sunitinib—kidney cancer	0.000982	0.00223	CcSEcCtD
Latanoprost—Chest pain—Sunitinib—kidney cancer	0.000982	0.00223	CcSEcCtD
Latanoprost—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	0.000976	0.00221	CcSEcCtD
Latanoprost—Dyspnoea—Erlotinib—kidney cancer	0.00097	0.0022	CcSEcCtD
Latanoprost—Pain—Vinblastine—kidney cancer	0.000968	0.0022	CcSEcCtD
Latanoprost—Inflammation—Doxorubicin—kidney cancer	0.000967	0.00219	CcSEcCtD
Latanoprost—Urinary tract infection—Paclitaxel—kidney cancer	0.000964	0.00219	CcSEcCtD
Latanoprost—Conjunctivitis—Paclitaxel—kidney cancer	0.000964	0.00219	CcSEcCtD
Latanoprost—Pain—Everolimus—kidney cancer	0.000964	0.00219	CcSEcCtD
Latanoprost—Nervous system disorder—Sorafenib—kidney cancer	0.00096	0.00218	CcSEcCtD
Latanoprost—Mediastinal disorder—Gemcitabine—kidney cancer	0.000958	0.00218	CcSEcCtD
Latanoprost—Rash—Temsirolimus—kidney cancer	0.000956	0.00217	CcSEcCtD
Latanoprost—Dermatitis—Temsirolimus—kidney cancer	0.000955	0.00217	CcSEcCtD
Latanoprost—Toxic epidermal necrolysis—Capecitabine—kidney cancer	0.000951	0.00216	CcSEcCtD
Latanoprost—Skin disorder—Sorafenib—kidney cancer	0.000951	0.00216	CcSEcCtD
Latanoprost—Headache—Temsirolimus—kidney cancer	0.000949	0.00215	CcSEcCtD
Latanoprost—Dizziness—Pazopanib—kidney cancer	0.000944	0.00214	CcSEcCtD
Latanoprost—Back pain—Vincristine—kidney cancer	0.000944	0.00214	CcSEcCtD
Latanoprost—Oedema—Sunitinib—kidney cancer	0.000942	0.00214	CcSEcCtD
Latanoprost—Pain—Erlotinib—kidney cancer	0.00093	0.00211	CcSEcCtD
Latanoprost—Erythema—Gemcitabine—kidney cancer	0.000926	0.0021	CcSEcCtD
Latanoprost—Nervous system disorder—Sunitinib—kidney cancer	0.000923	0.0021	CcSEcCtD
Latanoprost—Discomfort—Dactinomycin—kidney cancer	0.000919	0.00209	CcSEcCtD
Latanoprost—Skin disorder—Sunitinib—kidney cancer	0.000915	0.00208	CcSEcCtD
Latanoprost—Asthma—Capecitabine—kidney cancer	0.000913	0.00207	CcSEcCtD
Latanoprost—Rash—Pazopanib—kidney cancer	0.0009	0.00204	CcSEcCtD
Latanoprost—Dermatitis—Pazopanib—kidney cancer	0.000899	0.00204	CcSEcCtD
Latanoprost—Back pain—Gemcitabine—kidney cancer	0.000896	0.00203	CcSEcCtD
Latanoprost—Headache—Pazopanib—kidney cancer	0.000894	0.00203	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Sorafenib—kidney cancer	0.000892	0.00202	CcSEcCtD
Latanoprost—Oedema—Dactinomycin—kidney cancer	0.000891	0.00202	CcSEcCtD
Latanoprost—Angina pectoris—Capecitabine—kidney cancer	0.000889	0.00202	CcSEcCtD
Latanoprost—Bronchitis—Capecitabine—kidney cancer	0.000878	0.00199	CcSEcCtD
Latanoprost—Connective tissue disorder—Paclitaxel—kidney cancer	0.000875	0.00199	CcSEcCtD
Latanoprost—Dyspnoea—Sorafenib—kidney cancer	0.000872	0.00198	CcSEcCtD
Latanoprost—Dry eye—Doxorubicin—kidney cancer	0.000866	0.00197	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Sunitinib—kidney cancer	0.000858	0.00195	CcSEcCtD
Latanoprost—Upper respiratory tract infection—Capecitabine—kidney cancer	0.000848	0.00193	CcSEcCtD
Latanoprost—Dyspnoea—Sunitinib—kidney cancer	0.00084	0.00191	CcSEcCtD
Latanoprost—Pain—Sorafenib—kidney cancer	0.000837	0.0019	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.000812	0.00184	CcSEcCtD
Latanoprost—Pain—Sunitinib—kidney cancer	0.000805	0.00183	CcSEcCtD
Latanoprost—Mediastinal disorder—Paclitaxel—kidney cancer	0.000802	0.00182	CcSEcCtD
Latanoprost—Pruritus—Everolimus—kidney cancer	0.000798	0.00181	CcSEcCtD
Latanoprost—Oedema—Vincristine—kidney cancer	0.000796	0.00181	CcSEcCtD
Latanoprost—Urinary tract infection—Capecitabine—kidney cancer	0.000791	0.0018	CcSEcCtD
Latanoprost—Conjunctivitis—Capecitabine—kidney cancer	0.000791	0.0018	CcSEcCtD
Latanoprost—Chest pain—Gemcitabine—kidney cancer	0.000788	0.00179	CcSEcCtD
Latanoprost—Arthralgia—Gemcitabine—kidney cancer	0.000788	0.00179	CcSEcCtD
Latanoprost—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000783	0.00178	CcSEcCtD
Latanoprost—Nervous system disorder—Vincristine—kidney cancer	0.000781	0.00177	CcSEcCtD
Latanoprost—Hepatic function abnormal—Doxorubicin—kidney cancer	0.000779	0.00177	CcSEcCtD
Latanoprost—Discomfort—Gemcitabine—kidney cancer	0.000779	0.00177	CcSEcCtD
Latanoprost—Erythema—Paclitaxel—kidney cancer	0.000775	0.00176	CcSEcCtD
Latanoprost—Pruritus—Erlotinib—kidney cancer	0.00077	0.00175	CcSEcCtD
Latanoprost—Pain—Dactinomycin—kidney cancer	0.000762	0.00173	CcSEcCtD
Latanoprost—Eczema—Doxorubicin—kidney cancer	0.000758	0.00172	CcSEcCtD
Latanoprost—Oedema—Gemcitabine—kidney cancer	0.000756	0.00171	CcSEcCtD
Latanoprost—Eye pain—Doxorubicin—kidney cancer	0.000754	0.00171	CcSEcCtD
Latanoprost—Back pain—Paclitaxel—kidney cancer	0.00075	0.0017	CcSEcCtD
Latanoprost—Dizziness—Vinblastine—kidney cancer	0.000748	0.0017	CcSEcCtD
Latanoprost—Dizziness—Everolimus—kidney cancer	0.000746	0.00169	CcSEcCtD
Latanoprost—Nervous system disorder—Gemcitabine—kidney cancer	0.000741	0.00168	CcSEcCtD
Latanoprost—Skin disorder—Gemcitabine—kidney cancer	0.000734	0.00167	CcSEcCtD
Latanoprost—Vision blurred—Paclitaxel—kidney cancer	0.000731	0.00166	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Vincristine—kidney cancer	0.000726	0.00165	CcSEcCtD
Latanoprost—Dizziness—Erlotinib—kidney cancer	0.000719	0.00163	CcSEcCtD
Latanoprost—Connective tissue disorder—Capecitabine—kidney cancer	0.000718	0.00163	CcSEcCtD
Latanoprost—Rash—Everolimus—kidney cancer	0.000711	0.00161	CcSEcCtD
Latanoprost—Dermatitis—Everolimus—kidney cancer	0.00071	0.00161	CcSEcCtD
Latanoprost—Headache—Vinblastine—kidney cancer	0.000709	0.00161	CcSEcCtD
Latanoprost—Headache—Everolimus—kidney cancer	0.000706	0.0016	CcSEcCtD
Latanoprost—Pruritus—Sorafenib—kidney cancer	0.000692	0.00157	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000688	0.00156	CcSEcCtD
Latanoprost—Rash—Erlotinib—kidney cancer	0.000686	0.00156	CcSEcCtD
Latanoprost—Dermatitis—Erlotinib—kidney cancer	0.000685	0.00156	CcSEcCtD
Latanoprost—Headache—Erlotinib—kidney cancer	0.000681	0.00155	CcSEcCtD
Latanoprost—Pain—Vincristine—kidney cancer	0.000681	0.00155	CcSEcCtD
Latanoprost—Diplopia—Doxorubicin—kidney cancer	0.000681	0.00155	CcSEcCtD
Latanoprost—Dyspnoea—Gemcitabine—kidney cancer	0.000674	0.00153	CcSEcCtD
Latanoprost—Pruritus—Sunitinib—kidney cancer	0.000666	0.00151	CcSEcCtD
Latanoprost—Arthralgia—Paclitaxel—kidney cancer	0.00066	0.0015	CcSEcCtD
Latanoprost—Chest pain—Paclitaxel—kidney cancer	0.00066	0.0015	CcSEcCtD
Latanoprost—Mediastinal disorder—Capecitabine—kidney cancer	0.000659	0.00149	CcSEcCtD
Latanoprost—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000655	0.00149	CcSEcCtD
Latanoprost—Discomfort—Paclitaxel—kidney cancer	0.000652	0.00148	CcSEcCtD
Latanoprost—Dizziness—Sorafenib—kidney cancer	0.000647	0.00147	CcSEcCtD
Latanoprost—Pain—Gemcitabine—kidney cancer	0.000646	0.00147	CcSEcCtD
Latanoprost—Erythema—Capecitabine—kidney cancer	0.000636	0.00144	CcSEcCtD
Latanoprost—Oedema—Paclitaxel—kidney cancer	0.000633	0.00144	CcSEcCtD
Latanoprost—Dizziness—Sunitinib—kidney cancer	0.000623	0.00141	CcSEcCtD
Latanoprost—Nervous system disorder—Paclitaxel—kidney cancer	0.00062	0.00141	CcSEcCtD
Latanoprost—Rash—Sorafenib—kidney cancer	0.000617	0.0014	CcSEcCtD
Latanoprost—Dermatitis—Sorafenib—kidney cancer	0.000616	0.0014	CcSEcCtD
Latanoprost—Back pain—Capecitabine—kidney cancer	0.000615	0.0014	CcSEcCtD
Latanoprost—Skin disorder—Paclitaxel—kidney cancer	0.000614	0.00139	CcSEcCtD
Latanoprost—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	0.000613	0.00139	CcSEcCtD
Latanoprost—Headache—Sorafenib—kidney cancer	0.000613	0.00139	CcSEcCtD
Latanoprost—Vision blurred—Capecitabine—kidney cancer	0.000599	0.00136	CcSEcCtD
Latanoprost—Rash—Sunitinib—kidney cancer	0.000594	0.00135	CcSEcCtD
Latanoprost—Dermatitis—Sunitinib—kidney cancer	0.000593	0.00135	CcSEcCtD
Latanoprost—PTGFR—Prostaglandin Synthesis and Regulation—PTGS2—kidney cancer	0.00059	0.0197	CbGpPWpGaD
Latanoprost—Headache—Sunitinib—kidney cancer	0.00059	0.00134	CcSEcCtD
Latanoprost—Asthma—Doxorubicin—kidney cancer	0.000588	0.00134	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000576	0.00131	CcSEcCtD
Latanoprost—Angina pectoris—Doxorubicin—kidney cancer	0.000573	0.0013	CcSEcCtD
Latanoprost—Bronchitis—Doxorubicin—kidney cancer	0.000566	0.00128	CcSEcCtD
Latanoprost—Dyspnoea—Paclitaxel—kidney cancer	0.000564	0.00128	CcSEcCtD
Latanoprost—Rash—Dactinomycin—kidney cancer	0.000562	0.00128	CcSEcCtD
Latanoprost—Upper respiratory tract infection—Doxorubicin—kidney cancer	0.000547	0.00124	CcSEcCtD
Latanoprost—Chest pain—Capecitabine—kidney cancer	0.000542	0.00123	CcSEcCtD
Latanoprost—Arthralgia—Capecitabine—kidney cancer	0.000542	0.00123	CcSEcCtD
Latanoprost—Pain—Paclitaxel—kidney cancer	0.000541	0.00123	CcSEcCtD
Latanoprost—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000538	0.00122	CcSEcCtD
Latanoprost—Discomfort—Capecitabine—kidney cancer	0.000535	0.00121	CcSEcCtD
Latanoprost—Pruritus—Gemcitabine—kidney cancer	0.000535	0.00121	CcSEcCtD
Latanoprost—Tafluprost—PTGS2—kidney cancer	0.000527	1	CrCbGaD
Latanoprost—Dizziness—Vincristine—kidney cancer	0.000527	0.0012	CcSEcCtD
Latanoprost—Oedema—Capecitabine—kidney cancer	0.000519	0.00118	CcSEcCtD
Latanoprost—Conjunctivitis—Doxorubicin—kidney cancer	0.00051	0.00116	CcSEcCtD
Latanoprost—Urinary tract infection—Doxorubicin—kidney cancer	0.00051	0.00116	CcSEcCtD
Latanoprost—Nervous system disorder—Capecitabine—kidney cancer	0.000509	0.00116	CcSEcCtD
Latanoprost—Skin disorder—Capecitabine—kidney cancer	0.000504	0.00114	CcSEcCtD
Latanoprost—Rash—Vincristine—kidney cancer	0.000502	0.00114	CcSEcCtD
Latanoprost—Dermatitis—Vincristine—kidney cancer	0.000502	0.00114	CcSEcCtD
Latanoprost—Headache—Vincristine—kidney cancer	0.000499	0.00113	CcSEcCtD
Latanoprost—Rash—Gemcitabine—kidney cancer	0.000476	0.00108	CcSEcCtD
Latanoprost—Dermatitis—Gemcitabine—kidney cancer	0.000476	0.00108	CcSEcCtD
Latanoprost—Headache—Gemcitabine—kidney cancer	0.000473	0.00107	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000473	0.00107	CcSEcCtD
Latanoprost—Connective tissue disorder—Doxorubicin—kidney cancer	0.000463	0.00105	CcSEcCtD
Latanoprost—Dyspnoea—Capecitabine—kidney cancer	0.000463	0.00105	CcSEcCtD
Latanoprost—Pruritus—Paclitaxel—kidney cancer	0.000448	0.00102	CcSEcCtD
Latanoprost—Pain—Capecitabine—kidney cancer	0.000444	0.00101	CcSEcCtD
Latanoprost—Mediastinal disorder—Doxorubicin—kidney cancer	0.000425	0.000963	CcSEcCtD
Latanoprost—SLCO2B1—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	0.00042	0.014	CbGpPWpGaD
Latanoprost—Dizziness—Paclitaxel—kidney cancer	0.000418	0.000949	CcSEcCtD
Latanoprost—PTGFR—G alpha (q) signalling events—ITPR2—kidney cancer	0.000417	0.0139	CbGpPWpGaD
Latanoprost—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A3—kidney cancer	0.000414	0.0138	CbGpPWpGaD
Latanoprost—Erythema—Doxorubicin—kidney cancer	0.00041	0.000931	CcSEcCtD
Latanoprost—Rash—Paclitaxel—kidney cancer	0.000399	0.000905	CcSEcCtD
Latanoprost—Dermatitis—Paclitaxel—kidney cancer	0.000399	0.000904	CcSEcCtD
Latanoprost—Back pain—Doxorubicin—kidney cancer	0.000397	0.0009	CcSEcCtD
Latanoprost—Headache—Paclitaxel—kidney cancer	0.000396	0.000899	CcSEcCtD
Latanoprost—Vision blurred—Doxorubicin—kidney cancer	0.000386	0.000877	CcSEcCtD
Latanoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—ITPR2—kidney cancer	0.000373	0.0125	CbGpPWpGaD
Latanoprost—SLCO2B1—Transmembrane transport of small molecules—RYR1—kidney cancer	0.000371	0.0124	CbGpPWpGaD
Latanoprost—Pruritus—Capecitabine—kidney cancer	0.000367	0.000834	CcSEcCtD
Latanoprost—PTGFR—G alpha (q) signalling events—ANXA1—kidney cancer	0.00035	0.0117	CbGpPWpGaD
Latanoprost—Chest pain—Doxorubicin—kidney cancer	0.000349	0.000792	CcSEcCtD
Latanoprost—Arthralgia—Doxorubicin—kidney cancer	0.000349	0.000792	CcSEcCtD
Latanoprost—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000347	0.000787	CcSEcCtD
Latanoprost—Discomfort—Doxorubicin—kidney cancer	0.000345	0.000783	CcSEcCtD
Latanoprost—Dizziness—Capecitabine—kidney cancer	0.000343	0.000779	CcSEcCtD
Latanoprost—PTGFR—GPCR downstream signaling—OR4C13—kidney cancer	0.000337	0.0113	CbGpPWpGaD
Latanoprost—Oedema—Doxorubicin—kidney cancer	0.000335	0.000759	CcSEcCtD
Latanoprost—Nervous system disorder—Doxorubicin—kidney cancer	0.000328	0.000745	CcSEcCtD
Latanoprost—Rash—Capecitabine—kidney cancer	0.000327	0.000743	CcSEcCtD
Latanoprost—Dermatitis—Capecitabine—kidney cancer	0.000327	0.000742	CcSEcCtD
Latanoprost—Headache—Capecitabine—kidney cancer	0.000325	0.000738	CcSEcCtD
Latanoprost—Skin disorder—Doxorubicin—kidney cancer	0.000325	0.000738	CcSEcCtD
Latanoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—kidney cancer	0.000313	0.0105	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—OR4C13—kidney cancer	0.000306	0.0102	CbGpPWpGaD
Latanoprost—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000305	0.000692	CcSEcCtD
Latanoprost—Dyspnoea—Doxorubicin—kidney cancer	0.000298	0.000677	CcSEcCtD
Latanoprost—Pain—Doxorubicin—kidney cancer	0.000286	0.000649	CcSEcCtD
Latanoprost—Pruritus—Doxorubicin—kidney cancer	0.000237	0.000537	CcSEcCtD
Latanoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—ANXA1—kidney cancer	0.000231	0.00774	CbGpPWpGaD
Latanoprost—SLCO2B1—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	0.000221	0.0074	CbGpPWpGaD
Latanoprost—Dizziness—Doxorubicin—kidney cancer	0.000221	0.000502	CcSEcCtD
Latanoprost—SLCO2B1—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	0.000214	0.00715	CbGpPWpGaD
Latanoprost—SLCO2B1—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.000213	0.00713	CbGpPWpGaD
Latanoprost—SLCO2B1—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.000213	0.00713	CbGpPWpGaD
Latanoprost—SLCO2B1—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.000213	0.00713	CbGpPWpGaD
Latanoprost—Rash—Doxorubicin—kidney cancer	0.000211	0.000479	CcSEcCtD
Latanoprost—Dermatitis—Doxorubicin—kidney cancer	0.000211	0.000478	CcSEcCtD
Latanoprost—Headache—Doxorubicin—kidney cancer	0.00021	0.000476	CcSEcCtD
Latanoprost—SLC22A1—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	0.000188	0.00629	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—OR4C13—kidney cancer	0.000181	0.00604	CbGpPWpGaD
Latanoprost—PTGFR—GPCR ligand binding—ANXA1—kidney cancer	0.000176	0.00589	CbGpPWpGaD
Latanoprost—SLC22A1—Transmembrane transport of small molecules—RYR1—kidney cancer	0.000166	0.00557	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—LATS1—kidney cancer	0.000154	0.00513	CbGpPWpGaD
Latanoprost—SLC22A1—Neuronal System—KCNMA1—kidney cancer	0.000147	0.00493	CbGpPWpGaD
Latanoprost—SLC22A1—Transmission across Chemical Synapses—ACHE—kidney cancer	0.000142	0.00476	CbGpPWpGaD
Latanoprost—PTGFR—GPCR downstream signaling—AKAP13—kidney cancer	0.00014	0.00467	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—AMER1—kidney cancer	0.000131	0.00437	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—AKAP13—kidney cancer	0.000127	0.00424	CbGpPWpGaD
Latanoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—kidney cancer	0.000126	0.00422	CbGpPWpGaD
Latanoprost—SLC22A1—Transmission across Chemical Synapses—BCHE—kidney cancer	0.000124	0.00414	CbGpPWpGaD
Latanoprost—PTGFR—GPCR downstream signaling—ITPR2—kidney cancer	0.000119	0.00397	CbGpPWpGaD
Latanoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	0.000113	0.00379	CbGpPWpGaD
Latanoprost—SLCO2B1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	0.000113	0.00376	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—GPC3—kidney cancer	0.000109	0.00366	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—CER1—kidney cancer	0.000109	0.00366	CbGpPWpGaD
Latanoprost—SLC22A1—Neuronal System—ACHE—kidney cancer	0.000109	0.00364	CbGpPWpGaD
Latanoprost—SLCO2B1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	0.000109	0.00363	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—ITPR2—kidney cancer	0.000108	0.00361	CbGpPWpGaD
Latanoprost—PTGFR—GPCR downstream signaling—ANXA1—kidney cancer	9.96e-05	0.00333	CbGpPWpGaD
Latanoprost—SLC22A1—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	9.92e-05	0.00332	CbGpPWpGaD
Latanoprost—SLC22A1—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	9.58e-05	0.0032	CbGpPWpGaD
Latanoprost—SLC22A1—Transmembrane transport of small molecules—ATP7B—kidney cancer	9.56e-05	0.0032	CbGpPWpGaD
Latanoprost—SLC22A1—Transmembrane transport of small molecules—ANXA2—kidney cancer	9.56e-05	0.0032	CbGpPWpGaD
Latanoprost—SLC22A1—Transmembrane transport of small molecules—SLC5A3—kidney cancer	9.56e-05	0.0032	CbGpPWpGaD
Latanoprost—SLC22A1—Neuronal System—BCHE—kidney cancer	9.49e-05	0.00317	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—SFRP2—kidney cancer	9.3e-05	0.00311	CbGpPWpGaD
Latanoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—kidney cancer	9.1e-05	0.00304	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—ANXA1—kidney cancer	9.05e-05	0.00302	CbGpPWpGaD
Latanoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—kidney cancer	8.66e-05	0.0029	CbGpPWpGaD
Latanoprost—PTGFR—GPCR ligand binding—POMC—kidney cancer	8.64e-05	0.00289	CbGpPWpGaD
Latanoprost—SLCO2B1—Transmembrane transport of small molecules—ABCB1—kidney cancer	8.58e-05	0.00287	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—ACY1—kidney cancer	8.52e-05	0.00285	CbGpPWpGaD
Latanoprost—PTGFR—G alpha (q) signalling events—PIK3CA—kidney cancer	8.4e-05	0.00281	CbGpPWpGaD
Latanoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—kidney cancer	8.18e-05	0.00274	CbGpPWpGaD
Latanoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—kidney cancer	7.52e-05	0.00251	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—AKAP13—kidney cancer	7.5e-05	0.00251	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—CASP2—kidney cancer	7.5e-05	0.00251	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—PDHB—kidney cancer	7.25e-05	0.00242	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—GRB7—kidney cancer	6.86e-05	0.00229	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—CCBL1—kidney cancer	6.81e-05	0.00228	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—ITPR2—kidney cancer	6.38e-05	0.00213	CbGpPWpGaD
Latanoprost—SLC22A1—Transmission across Chemical Synapses—BRAF—kidney cancer	6.32e-05	0.00211	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—GLIPR1—kidney cancer	5.91e-05	0.00198	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—PPAT—kidney cancer	5.91e-05	0.00198	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—CTNNA1—kidney cancer	5.78e-05	0.00193	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—HSPB1—kidney cancer	5.75e-05	0.00192	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—EIF4EBP1—kidney cancer	5.75e-05	0.00192	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—APRT—kidney cancer	5.49e-05	0.00184	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—FH—kidney cancer	5.49e-05	0.00184	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—ANXA1—kidney cancer	5.34e-05	0.00179	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—TSC1—kidney cancer	5.34e-05	0.00179	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—PSMD7—kidney cancer	5.34e-05	0.00179	CbGpPWpGaD
Latanoprost—SLC22A1—Transmission across Chemical Synapses—RAF1—kidney cancer	5.28e-05	0.00177	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—FLT1—kidney cancer	5.18e-05	0.00173	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—GPC3—kidney cancer	5.16e-05	0.00173	CbGpPWpGaD
Latanoprost—SLC22A1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	5.04e-05	0.00169	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—CA2—kidney cancer	5.02e-05	0.00168	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—ALAD—kidney cancer	4.9e-05	0.00164	CbGpPWpGaD
Latanoprost—PTGFR—GPCR downstream signaling—POMC—kidney cancer	4.88e-05	0.00163	CbGpPWpGaD
Latanoprost—SLC22A1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	4.87e-05	0.00163	CbGpPWpGaD
Latanoprost—SLCO2B1—Transmembrane transport of small molecules—RAF1—kidney cancer	4.85e-05	0.00162	CbGpPWpGaD
Latanoprost—SLC22A1—Neuronal System—BRAF—kidney cancer	4.85e-05	0.00162	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—JUNB—kidney cancer	4.8e-05	0.0016	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—PAK1—kidney cancer	4.8e-05	0.0016	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—ST3GAL2—kidney cancer	4.78e-05	0.0016	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—ALDH1A1—kidney cancer	4.67e-05	0.00156	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—PGK1—kidney cancer	4.48e-05	0.0015	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—SLC5A3—kidney cancer	4.48e-05	0.0015	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—POMC—kidney cancer	4.43e-05	0.00148	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—LDHB—kidney cancer	4.39e-05	0.00147	CbGpPWpGaD
Latanoprost—SLC22A1—Neuronal System—RAF1—kidney cancer	4.05e-05	0.00135	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—IGF2—kidney cancer	3.92e-05	0.00131	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—CDKN2B—kidney cancer	3.9e-05	0.00131	CbGpPWpGaD
Latanoprost—SLC22A1—Transmembrane transport of small molecules—ABCB1—kidney cancer	3.84e-05	0.00129	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—CA9—kidney cancer	3.81e-05	0.00127	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—IGF1R—kidney cancer	3.79e-05	0.00127	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—RAF1—kidney cancer	3.65e-05	0.00122	CbGpPWpGaD
Latanoprost—SLC22A1—Transmission across Chemical Synapses—MAPK1—kidney cancer	3.62e-05	0.00121	CbGpPWpGaD
Latanoprost—PTGFR—GPCR downstream signaling—IL2—kidney cancer	3.61e-05	0.00121	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—IL2—kidney cancer	3.28e-05	0.0011	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—CRABP1—kidney cancer	3.24e-05	0.00108	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—HIF1A—kidney cancer	3.12e-05	0.00104	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—TSC2—kidney cancer	3.11e-05	0.00104	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—ITPR2—kidney cancer	3.01e-05	0.00101	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—KDR—kidney cancer	2.99e-05	0.000998	CbGpPWpGaD
Latanoprost—SLC22A1—Neuronal System—MAPK1—kidney cancer	2.77e-05	0.000928	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—APC—kidney cancer	2.75e-05	0.00092	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—KIT—kidney cancer	2.75e-05	0.00092	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—ACHE—kidney cancer	2.74e-05	0.000918	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—GSTT1—kidney cancer	2.74e-05	0.000918	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—MAPK3—kidney cancer	2.63e-05	0.000881	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—POMC—kidney cancer	2.62e-05	0.000875	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—SCARB1—kidney cancer	2.6e-05	0.000869	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—BRAF—kidney cancer	2.59e-05	0.000864	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—PTGS1—kidney cancer	2.57e-05	0.00086	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—PSMD7—kidney cancer	2.52e-05	0.000843	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—MAPK1—kidney cancer	2.51e-05	0.000838	CbGpPWpGaD
Latanoprost—PTGFR—GPCR downstream signaling—PIK3CA—kidney cancer	2.39e-05	0.000801	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—BCHE—kidney cancer	2.39e-05	0.000799	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—KRAS—kidney cancer	2.37e-05	0.000791	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—SLC5A5—kidney cancer	2.36e-05	0.00079	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—SLC2A1—kidney cancer	2.28e-05	0.000763	CbGpPWpGaD
Latanoprost—SLC22A1—Transmembrane transport of small molecules—RAF1—kidney cancer	2.18e-05	0.000727	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—PIK3CA—kidney cancer	2.17e-05	0.000727	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—RAF1—kidney cancer	2.16e-05	0.000722	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—RELA—kidney cancer	2.15e-05	0.000719	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—ERBB2—kidney cancer	2.14e-05	0.000714	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—MTOR—kidney cancer	2.11e-05	0.000705	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—CDKN1B—kidney cancer	1.98e-05	0.000661	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—IL2—kidney cancer	1.94e-05	0.000647	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—GSTP1—kidney cancer	1.9e-05	0.000636	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—CCND1—kidney cancer	1.89e-05	0.000631	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—JUN—kidney cancer	1.88e-05	0.000629	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—CTNNB1—kidney cancer	1.87e-05	0.000625	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—PTEN—kidney cancer	1.82e-05	0.000609	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—ABCB1—kidney cancer	1.8e-05	0.000602	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—GSTM1—kidney cancer	1.75e-05	0.000585	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—CYP1A1—kidney cancer	1.66e-05	0.000554	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—VEGFA—kidney cancer	1.64e-05	0.00055	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—MAPK3—kidney cancer	1.56e-05	0.00052	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—MYC—kidney cancer	1.51e-05	0.000506	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—MAPK1—kidney cancer	1.48e-05	0.000495	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—KRAS—kidney cancer	1.4e-05	0.000468	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—PIK3CA—kidney cancer	1.28e-05	0.00043	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—TP53—kidney cancer	1.24e-05	0.000416	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—POMC—kidney cancer	1.24e-05	0.000413	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—PTGS2—kidney cancer	9.86e-06	0.00033	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—PTEN—kidney cancer	8.59e-06	0.000287	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—PIK3CA—kidney cancer	6.06e-06	0.000203	CbGpPWpGaD
